The global Hospitals capecitabine market is experiencing robust growth due to the rising prevalence of cancer worldwide. In 2020, cancer accounted for around 10 million deaths worldwide, with breast cancer, colorectal cancer, and liver cancer being the leading causes of death. Capecitabine is an important chemotherapy medication used in the treatment of various types of cancer, including breast cancer, colorectal cancer, and gastric cancer. The drug is most widely sold under the brand name Xeloda and is often used in combination with other chemotherapy drugs.

Capecitabine is part of a group of antimetabolites called fluoropyrimidines, and it is administered orally. The drug was granted regulatory approval for medical use in 1998. For breast cancer treatment, capecitabine is used as a metastatic or monotherapy, while in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation.

The global Hospitals capecitabine market is being driven by the increasing usage of capecitabine in cancer treatment, the rise in RD activities for cancer therapeutics, and the increasing number of cancer awareness programs by various private and government organizations such as Cancer Research UK and American Cancer Society. The breast cancer segment is expected to account for the largest revenue share in the global Hospitals capecitabine market over the forecast period, followed by colorectal cancer and gastric cancer.

Request a sample Report of Hospitals capecitabine market https://www.reportsanddata.com/download-free-sample/261

However, the growth of the global Hospitals capecitabine market is significantly hampered due to various side-effects associated with the drug. Some serious side-effects of the drug include anemia, chest pain, diarrhea, vomiting, weakness, blood clotting problems, and cardiac-related issues such as cardiomyopathy. Kidney disease, DPD deficiency, and pregnancy are among other common contraindications of the drug.

The Hospitals capecitabine market in North America is expected to account for the largest revenue share over the forecast period, followed by Europe and Asia-Pacific. The surging prevalence of different types of cancers, including breast cancer and colorectal cancer, in countries in the region, the rising prevalence of unhealthy lifestyle-induced diseases such as obesity and hypertension, rapid increase in the global geriatric population, and increasing government funding for cancer research are major factors expected to fuel growth of the North America market over the forecast period.

Major companies operating in the global Hospitals capecitabine market include Cipla Inc., Genentech, Inc., F. Hoffmann-La Roche, Ranbaxy Laboratories Ltd., Teva Pharma B.V., Mylan N.V., Sandoz, Fresenius SE Co. KGaA, Zentiva N.V., Accord Healthcare Ltd., and Dr. Reddy Laboratories Ltd. In February 2021, Dr. Reddy’s Laboratories launched Capecitabine Tablets, USP, which is a therapeutic generic version of Xeloda Tablets, following approval by the U. S. FDA. In April 2020, Seattle Genetics announced U.S. FDA approval for its TUKYSA (Tucatinib) tablets indicated for breast cancer. TUKYSA, which is a tyrosine kinase inhibitor, along with Roche’s capecitabine and trastuzumab, is specifically indicated for metastatic HER2-positive breast cancer.

Overall, the global Hospitals capecitabine market is expected to register a steadily inclining revenue CAGR over the forecast period, although this growth may be hampered by the side-effects associated with the drug. Nonetheless, the increasing prevalence of cancer and the ongoing RD activities for cancer therapeutics are expected to continue driving growth in the global Hospitals capecitabine market.

Capecitabine is a chemotherapy drug used to treat different types of cancers, including breast, colorectal, and gastric cancers. The Hospitals capecitabine market is primarily driven by the increasing incidence of cancer and the rising demand for effective cancer treatments. Some of the key factors driving the growth of the Hospitals capecitabine market include:

Increasing Incidence of Cancer: The incidence of cancer is increasing globally due to factors such as aging population, unhealthy lifestyles, and environmental pollution. This increase in cancer incidence has resulted in a growing demand for effective cancer treatments, including capecitabine.

Growing Awareness of Cancer Treatment: As awareness of cancer and its treatment options increases, more patients are seeking medical help for their conditions. This trend has resulted in the growth of the Hospitals capecitabine market as more oncologists prescribe the drug to their patients.

Advancements in Cancer Research: Advancements in cancer research have led to the development of more effective cancer treatments, including capecitabine. The drug has been found to be effective in treating different types of cancer, which has led to increased adoption of the drug in the market.

Rising Healthcare Expenditure: The rising healthcare expenditure in developed and developing countries has increased access to cancer treatment, including capecitabine. Patients with cancer are now able to afford expensive treatments, which has driven the growth of the Hospitals capecitabine market

Government Initiatives: Government initiatives to increase access to cancer treatment and improve healthcare infrastructure have also contributed to the growth of the Hospitals capecitabine market. Governments in several countries are investing in cancer research and development and providing subsidies for cancer treatments, which has increased the availability of capecitabine to patients.

Request a customized copy of the report https://www.reportsanddata.com/request-customization-form/261

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs